Recent posts
Class-action lawsuits against publicly traded companies, which ironically are meant to protect investors like me, have officially jumped the shark. That was the only conclusion I could come to after... Read more »
CytRx (NASDAQ: CYTR) investors had a lot to be happy about last week. The good times came on Wednesday, Dec. 11, after the small cap biotech announced encouraging summary... Read more »
Anyone who follows the biotechnology industry surely is aware of the setback Cambridge, MA-based Sarepta Therapeutics (NASDAQ: SRPT) experienced this week after FDA changed their mind about the company’s ability... Read more »
Give the SEC a lot of credit…the headline they chose for their press release yesterday about public companies using social media could not have been more clear: “SEC Says Social Media... Read more »
Last night, Netflix disclosed that the Securities and Exchange Commission, @sec_news if you want to follow them on Twitter, intends to institute a cease and desist proceeding and/or bring a civil... Read more »
We are in the middle of a busy earnings season on Wall Street, which for an independent investor like me means listening to a lot of company conference calls. While that... Read more »
The recent Facebook IPO has brought to the front pages an issue that many ordinary investors have been asking themselves for a long time: “Is the system fair?” In Facebook’s case,... Read more »
[Editor’s Note: This letter was sent today to Dendreon chairman Richard Brewer.]
Dear Mr. Brewer:
Just over five months ago I wrote to you expressing serious concerns about the... Read more »
